The dermis is densely populated with immune component cells, such as Langerhans and dendritic cells, making it a highly responsive site for immune activation. Intradermal (ID) injection, which targets this layer, has long been recognized for its strong immune response and high delivery efficiency. However, despite these advantages, current intradermal injection techniques present certain challenges in medical practice.
To address these limitations, Terumo has developed an innovative intradermal injection device called IMMUCISE™.
Originally designed for vaccine delivery against infectious diseases, where it showed promising results in clinical trials, IMMUCISE™ has recently gained attention for its potential in ID lymphatic drug delivery. The skin's rich network of lymphatic vessels presents new opportunities, particularly for cancer therapy, where ID administration of high molecular weight drugs could offer superior lymphatic targeting.
We are excited to share new therapeutic possibilities both for infectious diseases vaccine and for cancer therapy.
RegisterKey Learning Objectives
- Discover the characteristics of dermis, suitable to activate immune responsiveness
- Advantages of a user-friendly device suitable for Intradermal Injection
- Presenting Clinical trial results obtained with Flu Vaccine
- Sharing Animal Study results for cancer therapy utilizing lymphatic drug delivery
